OnCo
trialsTrialRecruiting

Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma

A phase 2 trial of pemigatinib in gallbladder cancer and other biliary tract cancers, run by Haitao Zhao, MD, now recruiting.